Photo from academic.microsoft.com
T he success of renal transplantation has led physicians to waitlist increasingly older and obese recipients, populations at higher risk for cardiovascular complications and patient death. Growing importance is therefore… Click to show full abstract
T he success of renal transplantation has led physicians to waitlist increasingly older and obese recipients, populations at higher risk for cardiovascular complications and patient death. Growing importance is therefore attached to the management of the adverse cardiovascular risk profile of immunosuppressive therapy while maintaining adequate immunosuppressive efficacy. The prospective and randomized multicenter study from Spain by Torres et al. in the present issue of KI Reports is a significant contribution in this respect, and provides important information on the potential pitfalls. The trial selectively recruited candidates for renal transplantation at high risk to develop posttransplant diabetes mellitus (PTDM) either because of age $60 years or younger age (45–59 years) in combination with increased
Journal Title: Kidney International Reports
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!